ID: ALA3234430

Max Phase: Preclinical

Molecular Formula: C3H9O3PS

Molecular Weight: 156.14

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=P(O)(O)CCCS

Standard InChI:  InChI=1S/C3H9O3PS/c4-7(5,6)2-1-3-8/h8H,1-3H2,(H2,4,5,6)

Standard InChI Key:  UOLMNMNHGFGIDE-UHFFFAOYSA-N

Associated Targets(non-human)

Fe(3+)-Zn(2+) purple acid phosphatase 65 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 156.14Molecular Weight (Monoisotopic): 156.0010AlogP: 0.48#Rotatable Bonds: 3
Polar Surface Area: 57.53Molecular Species: ACIDHBA: 2HBD: 3
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 1.81CX Basic pKa: CX LogP: -0.64CX LogD: -3.00
Aromatic Rings: 0Heavy Atoms: 8QED Weighted: 0.41Np Likeness Score: 0.53

References

1. McGeary RP, Schenk G, Guddat LW..  (2014)  The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.,  76  [PMID:24583353] [10.1016/j.ejmech.2014.02.008]

Source